Growth Hormone Secretagogue

GHRP-2

Research Reagent · Laboratory Use Only

Quick Answer

What are the research findings on GHRP-2 as a growth hormone secretagogue?

GHRP-2 (pralmorelin) is a synthetic hexapeptide that stimulates growth hormone release via ghrelin receptor (GHSR-1a) activation. Preclinical and clinical studies demonstrate dose-dependent GH secretion, with research published in journals including the Journal of Clinical Endocrinology & Metabolism supporting its utility as a diagnostic tool for GH deficiency assessment.

PMID40277822↗DOI10.1210/jcem.86.2.7214↗⟳ Reconstitution Calculator
Scientific AbstractPMID 40277822 · 2025

Background Objectives

Our objective is to develop hormone-producing pituitary cells that can function in the same manner as the human body and provide more effective treatments than current hormone replacement therapy. We have already established a technique for generating hypothalamic-pituitary organoids using feeder-free human pluripotent stem cells (hPSCs) and demonstrated their effectiveness in vivo through transplantation into hypopituitary mouse models. To prospectively determine the upper limit of transplanting adenohypophyseal cells into humans, we investigated the human maximum secretion capacity of adrenocorticotropic hormone (ACTH) and growth hormone (GH).

Methods

We analyzed data from 28 patients with pituitary adenomas, among whom 16 evinced no abnormality of ACTH secretion and 12 showed no GH secretion on corticotropin-releasing hormone (CRH) and growth hormone-releasing hormone-2 (GHRP-2) stimulation testing.

Results

The average ACTH peak value after CRH stimulation tests was 97.2 pg/mL, and the average GH peak value after GHRP-2 stimulation tests was 25.1 ng/mL.

Conclusions

These data will likely serve as benchmarks of ACTH and GH secretion when transplanting cultured cells into humans.

Source:10.1210/jcem.86.2.7214
Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is GHRP-2?

GHRP-2 (Growth Hormone-Releasing Peptide-2) is a synthetic hexapeptide secretagogue used in clinical diagnostics to assess growth hormone (GH) secretion capacity in pituitary function testing. This research employed GHRP-2 as a pharmacological stimulus to determine maximal GH production in human subjects for regenerative medicine applications.

Mechanism of Action

GHRP-2 functions as a GH-releasing peptide that directly stimulates somatotroph cells in the anterior pituitary gland, bypassing hypothalamic regulation to trigger robust growth hormone secretion. Unlike natural GHRH (growth hormone-releasing hormone), GHRP-2 activates distinct ghrelin-receptor pathways, making it an effective diagnostic tool for measuring pituitary GH reserve capacity independent of normal physiological feedback loops.

Observed Laboratory Results

  • Average peak GH response to GHRP-2 stimulation: 25.1 ng/mL across 12 patients with intact GH secretion capacity
  • Patient cohort characteristics: Analysis of 28 pituitary adenoma patients; 12 demonstrated normal GH responsiveness to GHRP-2 challenge
  • Clinical benchmark application: Established maximal human GH secretion capacity serves as reference standard for evaluating hypothalamic-pituitary organoid transplantation outcomes in regenerative medicine protocols

Research Context

This data established critical physiological thresholds for somatotroph function to inform bioengineered pituitary cell transplantation safety parameters and expected hormone production ranges in human recipients.

Clinical Research Parameters
4 human studies

The following data represents formally registered clinical research studies and peer-reviewed human subject research indexed in public registries. All dose ranges, endpoints, and observations below reflect published study parameters — not recommendations. For research reference only.

Research Compliance Notice

All data presented on this page is for laboratory research purposes only. GHRP-2 is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 40277822) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.

Related Compounds

Other Growth Hormone Secretagogue Research Compounds

CJC-1295
The pursuit of pharmacological enhancement in sport has evolved from the widespread use of…
→
Ipamorelin
The pursuit of pharmacological enhancement in sport has evolved from the widespread use of…
→
Sermorelin
The pursuit of pharmacological enhancement in sport has evolved from the widespread use of…
→
Tesamorelin
Introduction: Overweight and obesity are becoming increasingly prevalent. Incretin-based o…
→
View all Growth Hormone Secretagogue compounds →